

518,575

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number  
**WO 2004/005544 A2**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number:  
PCT/EP2003/007111

(22) International Filing Date: 3 July 2003 (03.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0215509.1 4 July 2002 (04.07.2002) GB

(71) Applicant (for all designated States except AT, US): NO-  
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel  
(CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH  
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHIBOUT,  
Salah-Dine [FR/FR]; 5, route de Mulhouse, F-68720  
Tagolsheim (FR). GRENET, Olivier [FR/FR]; 26, rue  
Hopfet, F-68730 Blotzheim (FR). IMBERT, Georges  
[FR/FR]; 51, rue des Fleurs, F-68220 Buschwiller (FR).  
KEHREN, Jeanne [FR/FR]; 1, rue des Abeilles, F-68490

Bantzenheim (FR). STÄDTLER, Frank [DE/DE];  
Gartenweg 4, 79591 Eimeldingen (DE). WOLFGANG,  
Curt, Douglas [US/US]; 13331 Neerwinder Place, Ger-  
mantown, MD 20874 (US).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellec-  
tual Property, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM,  
TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (regional): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: MARKER GENES

(57) Abstract: Methods are disclosed for fast and accurate readout of kidney toxicity before it occurs and before it is demonstrated by histopathology examination. Ultimately this approach shall allow earlier compound selection. The twelve genes identified, namely Calbindin-D28k, KIM-1, OPN, EGF, Clusterin, VEGF, OAT-K1, Aldolase A, Aldolase B, Podocin, Alpha-2u and C4, were grouped and ultimately can be assessed in the form of a kit using PCR, a high throughput technology, in order to characterize and rank new compounds according to their anticipated general kidney toxicity. Also disclosed are methods for identifying agents useful in the treatment of kidney disease, methods for monitoring the efficacy of a treatment for kidney disease and kidney-specific vectors including the sequences of the disclosed genes, and a method for identifying a candidate gene associated with a biological process including kidney function.



WO 2004/005544 A2